ChemoMetec is a manufacturer of automated cell counting and analysis equipment. The company develops and produces high-precision instrumentation and consumables based on image cytometry and advanced image analysis. Its main products include the NucleoCounter® series, such as the NC-3000™ and NC-203™, and the XcytoMatic® series, including the XcytoMatic® 30 and XcytoMatic® 40. The company also produces disposable cassettes and consumables, such as the Via1-Cassette™, Via2-Cassette™, and Via3-Cassette™. ChemoMetec serves customers in the biotech, pharmaceutical, and academic segments, with applications in cell-based immunotherapy, cancer and stem cell research, drug development and production, bioprocessing, biomedical research, and the food and agricultural industry. The company was founded in 1997.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Instruments & Supplies Homepage chemometec.com
Sector Healthcare IR page investor.chemometec.com
Tags
cell counting, image cytometry, bioprocessing, cell therapy, stem cell research, laboratory equipment, consumables, NucleoCounter®, NC-3000™, NC-203™, NC-202™, NC-200™, XcytoMatic® 30, XcytoMatic® 40, Via1-Cassette™, Via2-Cassette™, Via3-Cassette™, XM™
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 30.1%
ROI 27.7%
ROIC 35.1%
Profit margin 37.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 5.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 495.57M 407.87M 444.4M 428.39M 281.12M
Net profit 186.4M 136.28M 178.66M 159.46M 88.35M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Major shareholder announcement - BlackRock, Inc. Bull 0 Bear 0 Routine

October 28, 2026 13:19 ET | Source: Chemometec A/S Follow Chemometec A/S

Share

ANNOUNCEMENT NO. 323

28 October 2026

Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 26 October 2026, BlackRock, Inc. increased its voting rights attached to shares in ChemoMetec A/S to 15.08%, thereby exceeding the 15% threshold pursuant to section 38(1) of the Danish Capital Markets Act.

At the same time, BlackRock, Inc. reduced its position in voting rights attached to financial instruments to 0.00%, whereby the aggregate position of voting rights attached to shares, pursuant to section 38(1) of the Danish Capital Markets Act, and voting rights attached to financial instruments, pursuant to section 39(1) of the Danish Capital Markets Act, remains unchanged at 15.08%.

BlackRock, Inc.’s position at that time was as follows:

  • Voting rights attached to shares: 15.08%

  • Voting rights through financial instruments: 0.00%

  • The total of both: 15.08%

Additional Information

Martin Helbo Behrens, CEO Tel.: (+45) 81 10 06 80

Phillip Massie Price, CFO Tel.: (+45) 81 10 06 80

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Major shareholder announcement - BlackRock, Inc. Bull 0 Bear 0 Routine

October 21, 2026 14:42 ET | Source: Chemometec A/S Follow Chemometec A/S

Share

ANNOUNCEMENT NO. 322

21 October 2026

Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 15 October 2026, BlackRock, Inc. reduced its voting rights attached to shares in ChemoMetec A/S to 14.97%, thereby falling below the 15% threshold pursuant to section 38(1) of the Danish Capital Markets Act.

At the same time, BlackRock, Inc. increased its position in voting rights attached to financial instruments to 0.11%, whereby the aggregate position of voting rights attached to shares, pursuant to section 38(1) of the Danish Capital Markets Act, and voting rights attached to financial instruments, pursuant to section 39(1) of the Danish Capital Markets Act, remains unchanged at 15.08%.

BlackRock, Inc.’s position at that time was as follows:

  • Voting rights attached to shares: 14.97%

  • Voting rights through financial instruments: 0.11%

  • The total of both: 15.08%

Additional Information

Martin Helbo Behrens, CEO Tel.: (+45) 81 10 06 80

Phillip Massie Price, CFO Tel.: (+45) 81 10 06 80

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

October 19, 2026 07:17 ET | Source: Chemometec A/S Follow Chemometec A/S

Share

ANNOUNCEMENT NO. 321

19 October 2026

ChemoMetec A/S will publish its financial results for the first quarter of the 2026/27 financial year on Thursday, November 5, 2026.

In this connection, ChemoMetec A/S will host a conference call on Friday, November 6, 2026, at 3:00 PM CET, during which CEO Martin Helbo Behrens and CFO Phillip Massie Price will present the financial results for the first quarter and answer questions.

The conference call will be held in English.

The webcast can be accessed via this link.

Additional Information

Martin Helbo Behrens, CEO Tel.: (+45) 81 10 06 80

Phillip Massie Price, CFO Tel.: (+45) 81 10 06 80

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Prompts

ChemoMetec (ticker CHEMM), listed in Denmark.

ETFs Holding ChemoMetec

ETF Weight in ETF Shares Market value As of
AVDS 0.10% 3,734 $ 380.928K Nov 16, 2026
DFIS 0.03% 19,950 $ 2.023M Nov 12, 2026
AVSD 0.02% 585 $ 59.679K Nov 16, 2026
AVDE 0.01% 14,717 $ 1.501M Nov 16, 2026
DFSI 0.01% 845 $ 85.686K Nov 12, 2026
DFIC 0.01% 7,988 $ 810.016K Nov 12, 2026
DFAI 0.00% 8,888 $ 901.28K Nov 12, 2026
DFAX 0.00% 5,442 $ 551.841K Nov 12, 2026